Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 39
Filter
1.
Biol Psychiatry ; 73(3): 280-8, 2013 Feb 01.
Article in English | MEDLINE | ID: mdl-22939991

ABSTRACT

BACKGROUND: Dopaminergic activity plays a role in mediating the rewarding aspects of abused drugs, including nicotine. Nicotine modulates the reinforcing properties of other motivational stimuli, yet the mechanisms of this interaction are poorly understood. This study aimed to ascertain the impact of nicotine exposure on neuronal activity associated with reinforcing outcomes in dependent smokers. METHODS: Smokers (n = 28) and control subjects (n = 28) underwent functional imaging during performance of a monetary incentive delay task. Using a randomized, counterbalanced design, smokers completed scanning after placement of a nicotine or placebo patch; nonsmokers were scanned twice without nicotine manipulation. In regions along dopaminergic pathway trajectories, we considered event-related activity for valence (reward/gain vs. punishment/loss), magnitude (small, medium, large), and outcome (successful vs. unsuccessful). RESULTS: Both nicotine and placebo patch conditions were associated with reduced activity in regions supporting anticipatory valence, including ventral striatum. In contrast, relative to controls, acute nicotine increased activity in dorsal striatum for anticipated magnitude. Across conditions, anticipatory valence-related activity in the striatum was negatively associated with plasma nicotine concentration, whereas the number of cigarettes daily correlated negatively with loss anticipation activity in the medial prefrontal cortex only during abstinence. CONCLUSIONS: These data suggest a partial dissociation in the state- and trait-specific effects of smoking and nicotine exposure on magnitude- and valence-dependent anticipatory activity within discrete reward processing brain regions. Such variability may help explain, in part, nicotine's impact on the reinforcing properties of nondrug stimuli and speak to the continued motivation to smoke and cessation difficulty.


Subject(s)
Corpus Striatum/drug effects , Motivation , Nicotine/administration & dosage , Smoking/physiopathology , Tobacco Use Disorder/physiopathology , Administration, Cutaneous , Adult , Brain Mapping , Corpus Striatum/physiopathology , Female , Humans , Image Processing, Computer-Assisted , Magnetic Resonance Imaging , Male , Middle Aged
2.
Clin Chim Acta ; 413(11-12): 978-84, 2012 Jun 14.
Article in English | MEDLINE | ID: mdl-22394455

ABSTRACT

BACKGROUND: Mecamylamine is a nicotine antagonist under investigation in combination with nicotine replacement for smoking treatment. METHODS: A simple, rapid and reliable liquid chromatography tandem mass spectrometry (LCMSMS) method was developed and validated for quantifying nicotine, cotinine, trans-3'-hydroxycotinine, norcotinine and mecamylamine in human urine. Chromatography was performed on a Synergi PolarRP column with a gradient of 0.1% formic acid and 0.1% formic acid in acetonitrile at 0.25 ml/min with an 8-min total runtime. Analytes were monitored by positive mode electrospray ionization and multiple reaction monitoring mass spectrometry. RESULTS: Linear dynamic ranges were 1-500 ng/ml for nicotine and norcotinine, 0.5-500 ng/ml for trans-3'-hydroxycotinine, 0.2-500 ng/ml for cotinine, and 0.1-100 ng/ml for mecamylamine; correlation coefficients were consistently greater than 0.99, and all calibrator concentrations were within 20% of target. Extensive endogenous and exogenous interferences were evaluated. At 3 concentrations spanning the linear dynamic range of the assay, mean extraction efficiencies from urine were 55.1-109.1% with analytical recovery (bias) 82.0-118.7% and total imprecision of 0.7-9.1%. Analytes were stable for 24h at room temperature, 72 h at 4 °C, 72 h in autosampler at 15 °C and after three freeze/thaw cycles. CONCLUSION: This method is useful for monitoring mecamylamine, nicotine and nicotine metabolites in smoking cessation and other clinical nicotine research.


Subject(s)
Chromatography, Liquid/methods , Cotinine/analogs & derivatives , Cotinine/urine , Mecamylamine/urine , Nicotine/urine , Tandem Mass Spectrometry/methods , Calibration , Humans , Sensitivity and Specificity , Smoking/urine , Smoking Cessation
3.
Biol Psychiatry ; 71(3): 206-13, 2012 Feb 01.
Article in English | MEDLINE | ID: mdl-22032832

ABSTRACT

BACKGROUND: The reinforcing effects of nicotine are mediated by brain regions that also support temporal difference error (TDE) processing; yet, the impact of nicotine on TDE is undetermined. METHODS: Dependent smokers (n = 21) and matched control subjects (n = 21) were trained to associate a juice reward with a visual cue in a classical conditioning paradigm. Subjects subsequently underwent functional magnetic resonance imaging sessions in which they were exposed to trials where they either received juice as temporally predicted or where the juice was withheld (negative TDE) and later received unexpectedly (positive TDE). Subjects were scanned in two sessions that were identical, except that smokers had a transdermal nicotine (21 mg) or placebo patch placed before scanning. Analysis focused on regions along the trajectory of mesocorticolimbic and nigrostriatal dopaminergic pathways. RESULTS: There was a reduction in TDE-related function in smokers in the striatum, which did not differ as a function of patch manipulation but was predicted by the duration (years) of smoking. Activation in midbrain regions was not impacted by group or drug condition. CONCLUSIONS: These data suggest a differential effect of smoking status on the neural substrates of reward in distinct dopaminergic pathway regions, which may be partially attributable to chronic nicotine exposure. The failure of transdermal nicotine to alter reward-related functional processes, either within smokers or between smokers and control subjects, implies that acute nicotine patch administration is insufficient to modify reward processing, which has been linked to abstinence-induced anhedonia in smokers and may play a critical role in smoking relapse.


Subject(s)
Conditioning, Classical/drug effects , Corpus Striatum/drug effects , Mesencephalon/drug effects , Nicotine/pharmacology , Reward , Tobacco Use Disorder/physiopathology , Adult , Case-Control Studies , Conditioning, Classical/physiology , Corpus Striatum/physiology , Corpus Striatum/physiopathology , Cues , Female , Functional Neuroimaging/methods , Functional Neuroimaging/psychology , Humans , Magnetic Resonance Imaging/methods , Magnetic Resonance Imaging/psychology , Male , Mesencephalon/physiology , Mesencephalon/physiopathology , Nicotine/administration & dosage , Nicotine/blood , Time Factors , Tobacco Use Cessation Devices , Tobacco Use Disorder/blood
4.
Ther Drug Monit ; 33(5): 609-18, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21860341

ABSTRACT

INTRODUCTION: Oral fluid collection is noninvasive and easily observed making it an attractive matrix for objectively determining smoking status. Despite large intersubject variability, cotinine oral fluid concentrations correlate with cigarettes smoked per day (CPD). Few studies, however, assessed nicotine markers in oral fluid other than cotinine; other markers might improve smoking status assessment and/or time of last cigarette. MATERIALS AND METHODS: Smoking histories and oral fluid specimens were collected from nontreatment-seeking light (1-10 CPD) and heavy smokers (greater than 10 CPD) and from environmentally exposed and nonexposed nonsmokers who provided written informed consent for this Institutional Review Board-approved study. Nicotine, cotinine, hydroxycotinine (OH-cotinine), and norcotinine oral fluid concentrations were quantified by liquid chromatography tandem mass spectrometry. RESULTS: Comparison of 1, 3, and 10 ng/mL oral fluid liquid chromatography tandem mass spectrometry cutoffs demonstrated that 10-ng/mL cutoffs performed optimally for cotinine, OH-cotinine, nicotine, and norcotinine identifying 98%, 97%, 88%, and 15% of self-reported smokers; 1% nonsmokers had greater than 10 ng/mL cotinine. No self-reported nonsmoker had greater than 10 ng/mL OH-cotinine, nicotine, or norcotinine. Norcotinine was only identified in smokers' oral fluid. Oral fluid nicotine, cotinine, and nicotine/cotinine ratios were correlated with time of last smoking (r = -0.53, -0.23, and -0.51; P < 0.05) and CPD (r = 0.35, 0.26, and 0.33; P < 0.01), respectively. DISCUSSION AND CONCLUSION: OH-cotinine performed slightly better than cotinine for distinguishing smokers from nonsmokers and should be considered as an additional oral fluid smoking indicator. Further research is required to determine if oral fluid norcotinine is a marker for distinguishing light and heavy smokers. Moderate correlations suggest nicotine, cotinine, and nicotine/cotinine ratios may be useful for determining smoking recency in "spot samples" collected during nicotine cessation treatment.


Subject(s)
Biomarkers/analysis , Nicotine/analysis , Nicotine/metabolism , Saliva/chemistry , Smoking , Administration, Oral , Adult , Cotinine/analogs & derivatives , Cotinine/analysis , Cotinine/metabolism , Female , Humans , Male , Middle Aged , Young Adult
5.
Ther Drug Monit ; 33(4): 443-52, 2011 Aug.
Article in English | MEDLINE | ID: mdl-21743375

ABSTRACT

OBJECTIVES: The purpose was to explore methadone and 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) umbilical cord disposition, correlate with maternal methadone dose and neonatal outcomes, and evaluate the window of drug detection in umbilical cord of in utero illicit drug exposure. METHODS: Subjects comprised 19 opioid-dependent pregnant women from 2 clinical studies, one comparing methadone and buprenorphine pharmacotherapy for opioid-dependence treatment and the second examining monetary reinforcement schedules to maintain drug abstinence. Correlations were calculated for methadone and EDDP umbilical cord concentrations and maternal methadone dose, and neonatal outcomes. Cocaine- and opiate-positive umbilical cord concentrations were compared with those in placenta and meconium, and urine specimens collected throughout gestation. RESULTS: Significant positive correlations were found for umbilical cord methadone concentrations and methadone mean daily dose, mean dose during the third trimester, and methadone cumulative daily dose. Umbilical cord EDDP concentrations and EDDP/methadone concentration ratios were positively correlated to newborn length, peak neonatal abstinence syndrome (NAS) score, and time-to-peak NAS score. Methadone concentrations and EDDP/methadone ratios in umbilical cord and placenta were positively correlated. Meconium identified many more cocaine- and opiate-positive specimens than did umbilical cord. CONCLUSIONS: Umbilical cord methadone concentrations were correlated to methadone doses. Also, our results indicate that methadone and EDDP concentrations might help to predict the NAS severity. Meconium proved to be more suitable than umbilical cord to detect in utero exposure to cocaine and opiates; however, umbilical cord could be useful when meconium is unavailable due to in utero or delayed expulsion.


Subject(s)
Cocaine/pharmacokinetics , Maternal-Fetal Exchange , Methadone/administration & dosage , Methadone/pharmacokinetics , Narcotics/pharmacokinetics , Pregnancy Complications/metabolism , Umbilical Cord/metabolism , Adult , Analgesics, Opioid/pharmacokinetics , Buprenorphine/pharmacokinetics , Buprenorphine/therapeutic use , Cocaine/urine , Dose-Response Relationship, Drug , Female , Humans , Infant, Newborn , Meconium/metabolism , Narcotics/urine , Neonatal Abstinence Syndrome/drug therapy , Neonatal Abstinence Syndrome/metabolism , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/metabolism , Opioid-Related Disorders/urine , Placenta/metabolism , Pregnancy , Pregnancy Complications/drug therapy , Pregnancy Complications/urine , Pregnancy Outcome , Pyrrolidines/pharmacokinetics
6.
Addiction ; 106(7): 1325-34, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21438939

ABSTRACT

AIMS: Many cities have banned indoor smoking in public places. Thus, an updated recommendation for a breath carbon monoxide (CO) cut-off is needed that optimally determines smoking status. We evaluated and compared the performance of breath CO and semiquantitative cotinine immunoassay test strips (urine and saliva NicAlert®) alone and in combination. DESIGN: Cross-sectional study. SETTING: Urban drug addiction research and treatment facility. PARTICIPANTS: Ninety non-treatment-seeking smokers and 82 non-smokers. MEASUREMENTS: Participants completed smoking histories and provided breath CO, urine and saliva specimens. Urine and saliva specimens were assayed for cotinine by NicAlert® and liquid chromatography-tandem mass spectrometry (LCMSMS). FINDINGS: An optimal breath CO cut-off was established using self-report and LCMSMS analysis of cotinine, an objective indicator, as reference measures. Performance of smoking indicators and combinations were compared to the reference measures. Breath CO ≥5 parts per million (p.p.m.) optimally discriminated smokers from non-smokers. Saliva NicAlert® performance was less effective than the other indicators. CONCLUSIONS: In surveys of smokers and non-smokers in areas with strong smoke-free laws, the breath carbon monoxide cut-off that discriminates most effectively appears to be ≥5 p.p.m. rather than the ≥10 p.p.m. cut-off often used. These findings may not generalize to clinical trials, regions with different carbon monoxide pollution levels or areas with less stringent smoke-free laws.


Subject(s)
Carbon Monoxide/analysis , Cotinine/analysis , Reagent Kits, Diagnostic/standards , Saliva/chemistry , Smoking/metabolism , Tobacco Smoke Pollution/analysis , Adolescent , Adult , Biomarkers/metabolism , Breath Tests , Cotinine/pharmacokinetics , Cross-Sectional Studies , Data Interpretation, Statistical , Female , Half-Life , Humans , Immunoassay/standards , Male , Reference Standards , Self Report , Sensitivity and Specificity , Smoking/legislation & jurisprudence , Tandem Mass Spectrometry , Tobacco Smoke Pollution/legislation & jurisprudence , Urban Population
7.
Clin Chem ; 57(3): 449-58, 2011 Mar.
Article in English | MEDLINE | ID: mdl-21245372

ABSTRACT

BACKGROUND: Few investigations have used placenta as an alternative matrix to detect in utero drug exposure, despite its availability at the time of birth and the large amount of sample. Methadone-maintained opioid-dependent pregnant women provide a unique opportunity to examine the placental disposition of methadone and metabolite [2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP)], to explore their correlations with maternal methadone dose and neonatal outcomes, and to test the ability to detect in utero exposure to illicit drugs. METHODS: We calculated the correlations of placental methadone and EDDP concentrations and their correlations with maternal methadone doses and neonatal outcomes. Cocaine- and opiate-positive placenta results were compared with the results for meconium samples and for urine samples collected throughout gestation. RESULTS: Positive correlations were found between placental methadone and EDDP concentrations (r=0.685), and between methadone concentration and methadone dose at delivery (r=0.542), mean daily dose (r=0.554), mean third-trimester dose (r=0.591), and cumulative daily dose (r=0.639). The EDDP/methadone concentration ratio was negatively correlated with cumulative daily dose (r=-0.541) and positively correlated with peak neonatal abstinence syndrome (NAS) score (r=0.513). Placental EDDP concentration was negatively correlated with newborn head circumference (r=-0.579). Cocaine and opiate use was detected in far fewer placenta samples than in thrice-weekly urine and meconium samples, a result suggesting a short detection window for placenta. CONCLUSIONS: Quantitative methadone and EDDP measurement may predict NAS severity. The placenta reflects in utero drug exposure for a shorter time than meconium but may be useful when meconium is unavailable or if documentation of recent exposure is needed.


Subject(s)
Maternal Exposure , Methadone/administration & dosage , Opiate Substitution Treatment/methods , Opioid-Related Disorders/metabolism , Placenta/metabolism , Pregnancy Complications/metabolism , Analgesics, Opioid/urine , Apgar Score , Birth Weight/drug effects , Body Size/drug effects , Cephalometry , Cocaine/urine , Female , Gestational Age , Humans , Infant, Newborn , Maternal Exposure/adverse effects , Meconium/chemistry , Methadone/pharmacokinetics , Methadone/therapeutic use , Opioid-Related Disorders/rehabilitation , Opioid-Related Disorders/urine , Pregnancy , Pregnancy Complications/rehabilitation , Pregnancy Complications/urine , Pregnancy Outcome , Pregnancy Trimesters , Pyrrolidines/metabolism , Tissue Distribution
8.
Psychopharmacology (Berl) ; 213(1): 29-42, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20862456

ABSTRACT

RATIONALE: Beyond the amelioration of deprivation-induced impairments, and in contrast to effects on attentional processes, the cognitive-enhancing properties of nicotine on working memory (WM) operations remain unclear. OBJECTIVES: In an effort to elucidate potential enhancing effects, we explored the impact of transdermal nicotine on neural functioning in minimally deprived smokers and, in addition, assessed differences between smokers and non-smokers using a mixed block/event-related fMRI design that attempted to isolate specific central executive operations (attentional switch events) within general WM function (task blocks). METHODS: In task blocks, participants performed a continuous counting paradigm that required the simultaneous maintenance of, and frequent switching of attentional focus between, two running tallies in WM on some trials. Cigarette smokers (n = 30) were scanned twice, once each with a nicotine and placebo patch, while non-smokers (n = 27) were scanned twice with no patch. RESULTS: Across both groups, task blocks were associated with bilateral activation, notably in medial and lateral prefrontal cortex (PFC), anterior insula, and parietal regions, whereas individual attentional switch trials were associated with activation in a similar, but predominantly left-lateralized network. Within the smoker group, although nicotine increased heart rate, altered performance and mood, and reduced tobacco cravings, no acute drug (state-like) effect on brain activity was detected for either the task or switch effects. However, relative to non-smokers, smokers showed greater tonic activation in medial superior frontal cortex, right anterior insula, and bilateral anterior PFC throughout task blocks (trait-like effect). CONCLUSIONS: These data suggest smokers require recruitment of additional WM and supervisory control operations during task performance.


Subject(s)
Brain/physiopathology , Executive Function/physiology , Memory, Short-Term/physiology , Nicotine/pharmacology , Smoking/physiopathology , Administration, Cutaneous , Adult , Brain/drug effects , Executive Function/drug effects , Female , Humans , Magnetic Resonance Imaging , Male , Memory, Short-Term/drug effects , Middle Aged , Nicotine/administration & dosage , Placebos , Psychomotor Performance/drug effects , Psychomotor Performance/physiology , Tobacco Use Disorder/physiopathology
9.
Anal Bioanal Chem ; 400(1): 69-78, 2011 Apr.
Article in English | MEDLINE | ID: mdl-21125263

ABSTRACT

A liquid chromatography tandem mass spectrometry method for buprenorphine (BUP), norbuprenorphine (NBUP), methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), cocaine, benzoylecgonine, ecgonine methyl ester (EME), morphine, codeine, 6-acetylmorphine, heroin, 6-acetylcodeine, cotinine, and trans-3'-hydroxycotinine quantification in sweat was developed and comprehensively validated. Sweat patches were mixed with 6 mL acetate buffer at pH 4.5, and supernatant extracted with Strata-XC-cartridges. Reverse-phase separation was achieved with a gradient mobile phase of 0.1% formic acid and acetonitrile in 15 min. Quantification was achieved by multiple reaction monitoring of two transitions per compound. The assay was a linear 1-1,000 ng/patch, except EME 5-1,000 ng/patch. Intra-, inter-day and total imprecision were <10.1%CV, analytical recovery 87.2-107.7%, extraction efficiency 35.3-160.9%, and process efficiency 25.5-91.7%. Ion suppression was detected for EME (-63.3%) and EDDP (-60.4%), and enhancement for NBUP (42.6%). Deuterated internal standards compensated for these effects. No carryover was detected, and all analytes were stable for 24 h at 22 °C, 72 h at 4 °C, and after three freeze/thaw cycles. The method was applied to weekly sweat patches from an opioid-dependent BUP-maintained pregnant woman; 75.0% of sweat patches were positive for BUP, 93.8% for cocaine, 37.5% for opiates, 6.3% for methadone and all for tobacco biomarkers. This method permits a fast and simultaneous quantification of 14 drugs and metabolites in sweat patches, with good selectivity and sensitivity.


Subject(s)
Analgesics, Opioid/analysis , Buprenorphine/analysis , Chromatography, Liquid/methods , Methadone/analysis , Nicotine/analysis , Sweat/chemistry , Tandem Mass Spectrometry/methods , Humans
10.
Anal Bioanal Chem ; 398(2): 915-24, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20652688

ABSTRACT

A method for simultaneous determination of buprenorphine (BUP), norbuprenorphine (NBUP), methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), cocaine, benzoylecgonine (BE), ecgonine methyl ester (EME), anhydroecgonine methyl ester (AEME), morphine, codeine, 6-acetylmorphine (6AM), heroin, 6-acetylcodeine (6AC), nicotine, cotinine, and trans-3'-hydroxycotinine (OH-cotinine) by liquid chromatography tandem mass spectrometry in oral fluid (OF) was developed and extensively validated. Acetonitrile (800 µL) and OF (250 µL) were added to a 96-well Isolute-PPT+protein precipitation plate. Reverse-phase separation was achieved in 16 min and quantification was performed by multiple reaction monitoring. The assay was linear from 0.5 or 1 to 500 µg/L. Intraday, interday, and total imprecision were less than 13% (n = 20), analytical recovery was 92-114% (n = 20), extraction efficiencies were more than 77% (n = 5), and process efficiencies were more than 45% (n = 5). Although ion suppression was detected for EME, cocaine, morphine, 6AC, and heroin (less than 56%) and enhancement was detected for BE and nicotine (less than 316%), deuterated internal standards compensated for these effects. The method was sensitive (limit of detection 0.2-0.8 µg/L) and specific (no interferences) except that 3-hydroxy-4-methoxyamphetamine interfered with AEME. No carryover was detected, and all analytes were stable for 24 h at 22 °C, for 72 h at 4 °C, and after three freeze-thaw cycles, except cocaine, 6AC, and heroin (22-97% loss). The method was applied to 41 OF specimens collected throughout pregnancy with a Salivette® OF collection device from an opioid-dependent BUP-maintained pregnant woman. BUP ranged from 0 to 7,400 µg/L, NBUP from 0 to 71 µg/L, methadone from 0 to 3 µg/L, nicotine from 32 to 5,020 µg/L, cotinine from 125 to 508 µg/L, OH-cotinine from 11 to 51 µg/L, cocaine from 0 to 419 µg/L, BE from 0 to 351 µg/L, EME from 0 to 286 µg/L, AEME from 0 to 7 µg/L, morphine from 0 to 22 µg/L, codeine from 0 to 1 µg/L, 6AM from 0 to 4 µg/L, and heroin from 0 to 2 µg/L. All specimens tested negative for EDDP and 6AC. This method permits a fast and simultaneous quantification of 16 drugs and metabolites in OF, with good selectivity and sensitivity.


Subject(s)
Buprenorphine/analysis , Cocaine/analysis , Methadone/analysis , Narcotics/analysis , Nicotine/analysis , Saliva/chemistry , Tandem Mass Spectrometry/methods , Anesthetics, Local/analysis , Anesthetics, Local/metabolism , Buprenorphine/metabolism , Chromatography, Liquid/methods , Cocaine/metabolism , Female , Ganglionic Stimulants/analysis , Ganglionic Stimulants/metabolism , High-Throughput Screening Assays/methods , Humans , Limit of Detection , Methadone/metabolism , Narcotics/metabolism , Nicotine/metabolism , Pregnancy
11.
Ther Drug Monit ; 32(2): 206-15, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20216119

ABSTRACT

Buprenorphine is approved as pharmacotherapy for opioid dependence in nonpregnant patients in multiple countries and is currently under investigation for pregnant women in the United States and Europe. This research evaluates the disposition of buprenorphine, opiates, cocaine, and metabolites in five term placentas from a US cohort. Placenta and matched meconium concentrations were compared, and relationships among maternal buprenorphine dose, placenta concentrations, and neonatal outcomes after controlled administration during gestation were investigated. Buprenorphine and/or metabolites were detected in all placenta specimens and were uniformly distributed across this tissue (coefficient of variation less than 27.5%, four locations), except for buprenorphine in three placentas. In two of these, buprenorphine was not detected in some locations and in the third placenta was totally absent. Median (range) concentrations were 1.6 ng/g buprenorphine (not detected to 3.2), 14.9 ng/g norbuprenorphine (6.2-24.2), 3 ng/g buprenorphine-glucuronide (1.3-5.0), and 14.7 ng/g norbuprenorphine-glucuronide (11.4-25.8). Placenta is a potential alternative matrix for detecting in utero buprenorphine exposure, but at lower concentrations (15- to 70-fold) than in meconium. Statistically significant correlations were observed for mean maternal daily dose from enrollment to delivery and placenta buprenorphine-glucuronide concentration and for norbuprenorphine-glucuronide concentrations and time to neonatal abstinence syndrome onset and duration, for norbuprenorphine/norbuprenorphine-glucuronide ratio and maximum neonatal abstinence syndrome score, and newborn length. Analysis of buprenorphine and metabolites in this alternative matrix, an abundant waste product available at the time of delivery, may be valuable for prediction of neonatal outcomes for clinicians treating newborns of buprenorphine-exposed women.


Subject(s)
Buprenorphine/administration & dosage , Buprenorphine/metabolism , Maternal-Fetal Exchange/drug effects , Maternal-Fetal Exchange/physiology , Placenta/drug effects , Placenta/metabolism , Adult , Buprenorphine/analysis , Cohort Studies , Female , Humans , Infant, Newborn , Male , Opioid-Related Disorders/drug therapy , Opioid-Related Disorders/metabolism , Pregnancy , Pregnancy Outcome , Prenatal Exposure Delayed Effects/metabolism , Treatment Outcome , Young Adult
12.
J Anal Toxicol ; 34(1): 17-25, 2010.
Article in English | MEDLINE | ID: mdl-20109298

ABSTRACT

Opiates, cocaine, and metabolites were quantified by liquid chromatography-mass spectrometry (LC-MS) in 284 urine specimens, collected thrice weekly, to monitor possible drug relapse in 15 pregnant heroin-dependent women. Opiates were detected in 149 urine specimens (52%) with limits of quantification (LOQ) of 10-50 microg/L. Morphine, morphine-3-glucuronide, and/or morphine-6-glucuronide were positive in 121 specimens; 6-acetylmorphine, a biomarker of heroin ingestion, was quantifiable in only 7. No heroin, 6-acetylcodeine, papaverine, or noscapine were detected. One hundred and sixty-five urine specimens (58%) from all 15 participants were positive for one or more cocaine analytes (LOQ 10-100 microg/L). Ecgonine methylester (EME) and/or benzoylecgonine were the major cocaine biomarkers in 142. Anhydroecgonine methylester, a biomarker of smoked cocaine, was positive in six; cocaethylene and/or ecgonine ethylester, biomarkers of cocaine and ethanol co-ingestion, were found in 25. At the current Substance Abuse Mental Health Services Administration cutoffs for total morphine (2000 microg/L), codeine (2000 microg/L), 6-acetylmorphine (10 microg/L), and benzoylecgonine (100 microg/L), 16 opiate- and 29 cocaine-positive specimens were identified. Considering 100 microg/L EME as an additional urinary cocaine biomarker would identify 51 more positive cocaine specimens. Of interest is the differential pattern of opiate and cocaine biomarkers observed after LC-MS as compared to gas chromatography-mass spectrometry analysis.


Subject(s)
Cocaine-Related Disorders/urine , Cocaine/urine , Methadone/urine , Morphine Derivatives/urine , Narcotics/urine , Opioid-Related Disorders/urine , Adult , Chromatography, High Pressure Liquid , Cocaine-Related Disorders/diagnosis , Female , Humans , Methadone/therapeutic use , Narcotics/therapeutic use , Opioid-Related Disorders/diagnosis , Opioid-Related Disorders/rehabilitation , Pregnancy , Spectrometry, Mass, Electrospray Ionization/methods , Substance Abuse Detection/methods , Urinalysis/methods , Young Adult
13.
J Anal Toxicol ; 34(8): 498-505, 2010 Oct.
Article in English | MEDLINE | ID: mdl-21819795

ABSTRACT

Buprenorphine is under investigation in the U.S. as pharmacotherapy for opioid-dependent pregnant women. Buprenorphine and metabolites were quantified in umbilical cord specimens from women receiving daily buprenorphine doses. Correlations between maternal buprenorphine dose, buprenorphine and metabolite umbilical cord concentrations, and neonatal outcomes were investigated, as well as the ability to identify heroin and cocaine relapse during pregnancy. Umbilical cord concentrations were compared to those of matched umbilical cord plasma and meconium. Buprenorphine metabolites were detected in all cords, but buprenorphine itself was absent. Concentration ranges were 1.2-5.1 ng/g norbuprenorphine, 1.7-4.2 ng/g buprenorphine-glucuronide, and 8.3-23 ng/g norbuprenorphine-glucuronide. Cord concentrations were similar to those in plasma, and lower (16-210-fold), although statistically correlated, than those in meconium. Significant positive correlations were observed for buprenorphine-glucuronide concentrations in umbilical cord and mean maternal BUP daily dose throughout pregnancy and third trimester, but buprenorphine biomarker concentrations did not predict neonatal outcomes. Opiate concentrations were lower (200-fold) in umbilical cord than in meconium, and when cocaine was present in meconium, it was not identified in cord. Umbilical cord can serve as an alternative matrix for identifying prenatal drug-exposure, but is much less sensitive than meconium. Buprenorphine provided a controlled drug administration model for evaluating drug disposition in the maternal-fetal dyad.


Subject(s)
Analgesics, Opioid/pharmacokinetics , Buprenorphine/pharmacokinetics , Opiate Substitution Treatment , Adult , Analgesics, Opioid/blood , Apgar Score , Birth Weight , Buprenorphine/blood , Dose-Response Relationship, Drug , Drug Monitoring/methods , Female , Fetal Blood , Gestational Age , Humans , Infant, Newborn/blood , Length of Stay , Maternal Exposure , Meconium/chemistry , Meconium/metabolism , Pregnancy
14.
Article in English | MEDLINE | ID: mdl-19945361

ABSTRACT

An LCMSMS method was developed and fully validated for the simultaneous quantification of buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) in 0.5mL plasma, fulfilling confirmation criteria with two transitions for each compound with acceptable relative ion intensities. Transitions monitored were 468.3>396.2 and 468.3>414.3 for BUP, 414.3>340.1 and 414.3>326.0 for NBUP, 644.3>468.1 and 644.3>396.3 for BUP-Gluc, and 590.3>414.3 and 590.3>396.2 for NBUP-Gluc. Linearity was 0.1-50ng/mL for BUP and BUP-Gluc, and 0.5-50ng/mL for NBUP and NBUP-Gluc. Intra-day, inter-day, and total assay imprecision (%RSD) were <16.8%, and analytical recoveries were 88.6-108.7%. Extraction efficiencies ranged from 71.1 to 87.1%, and process efficiencies 48.7 to 127.7%. All compounds showed ion enhancement, except BUP-Gluc that demonstrated ion suppression: variation between 10 different blank plasma specimens was <9.1%. In six umbilical cord plasma specimens from opioid-dependent pregnant women receiving 14-24mg/day BUP, NBUP-Gluc was the predominant metabolite (29.8+/-7.6ng/mL), with BUP-Gluc (4.6+/-4.8ng/mL), NBUP (1.5+/-0.8ng/mL) and BUP (0.4+/-0.2ng/mL). Although BUP biomarkers can be quantified in umbilical cord plasma in low ng/mL concentrations, the significance of these data as predictors of neonatal outcomes is currently unknown.


Subject(s)
Buprenorphine/analogs & derivatives , Buprenorphine/blood , Chromatography, Liquid/methods , Fetal Blood/chemistry , Glucuronides/blood , Tandem Mass Spectrometry/methods , Buprenorphine/administration & dosage , Female , Humans , Linear Models , Narcotic Antagonists/administration & dosage , Narcotic Antagonists/blood , Opioid-Related Disorders/blood , Opioid-Related Disorders/drug therapy , Pregnancy , Reproducibility of Results , Sensitivity and Specificity
15.
Anal Bioanal Chem ; 395(7): 2349-57, 2009 Dec.
Article in English | MEDLINE | ID: mdl-19838828

ABSTRACT

An analytical procedure was developed and validated for the simultaneous identification and quantification of nicotine, cotinine, trans-3'-hydroxycotinine, and norcotinine in 0.5 mL of human oral fluid collected with the Quantisal oral fluid collection device. Solid phase extraction and liquid chromatography-tandem mass spectrometry with multiple reaction monitoring were utilized. Endogenous and exogenous interferences were extensively evaluated. Limits of quantification were empirically identified by decreasing analyte concentrations. Linearity was from 1 to 2,000 ng/mL for nicotine and norcotinine, 0.5 to 2,000 ng/mL for trans-3'-hydroxycotinine, and 0.2 to 2,000 ng/mL for cotinine. Correlation coefficients for calibration curves were >0.99 and analytes quantified within +/-13% of target at all calibrator concentrations. Suitable analytical recovery (>91%) was achieved with extraction efficiencies >56% and matrix effects <29%. This assay will be applied to the quantification of nicotine and metabolites in oral fluid in a clinical study determining the most appropriate nicotine biomarker concentrations differentiating active, passive, and environmental nicotine exposure.


Subject(s)
Cotinine/analogs & derivatives , Cotinine/chemistry , Gingival Crevicular Fluid/chemistry , Nicotine/chemistry , Chromatography, Liquid/methods , Humans , Mass Spectrometry/methods , Reproducibility of Results , Sensitivity and Specificity
16.
J Chromatogr B Analyt Technol Biomed Life Sci ; 877(29): 3537-42, 2009 Nov 01.
Article in English | MEDLINE | ID: mdl-19748838

ABSTRACT

An LC-MS/MS method for the simultaneous quantification of nicotine, cotinine, trans-3'-hydroxycotinine and norcotinine in human plasma was developed and fully validated. Potential endogenous and exogenous interferences were extensively evaluated and limits of quantification were determined by decreasing analyte concentration. Analytical ranges were 1-500 ng/mL for nicotine and cotinine, 5-500 ng/mL for trans-3'-hydroxycotinine and norcotinine. Mean intra- and inter-assay analytical recoveries were between 101.9 and 116.8%, and intra- and inter-assay imprecision were less than 11% RSD for all analytes: parameters were evaluated at three different concentrations across the linear range of the assay. Extraction efficiency was > or = 70% for all analytes. This validated method is useful for the determination of nicotine and metabolites in human plasma to support research on the role of nicotine biomarkers on neuronal systems mediating cognitive and affective processes and to differentiate active, passive and environmental exposure.


Subject(s)
Chromatography, Liquid/methods , Cotinine/analogs & derivatives , Cotinine/blood , Nicotine/blood , Tandem Mass Spectrometry/methods , Humans , Sensitivity and Specificity
17.
J Chromatogr B Analyt Technol Biomed Life Sci ; 877(27): 3065-71, 2009 Oct 01.
Article in English | MEDLINE | ID: mdl-19656745

ABSTRACT

A liquid chromatography mass spectrometric selected reaction monitoring mode (SRM) method for methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP), cocaine, benzoylecgonine (BE), 6-acetylmorphine, morphine and codeine quantification in human umbilical cord was developed and fully validated. Analytes were extracted from homogenized tissue (1g) by solid phase extraction. Linearity was 2.5-500ng/g, except for methadone (10-2000ng/g). Method imprecision was <12.7%CV with analytical recovery 85.9-112.7%, extraction efficiency >59.2%, matrix effect 4.5-39.5%, process efficiency 48.6-92.6% and stability >84.6%. Analysis of an umbilical cord following controlled methadone administration and illicit drug use contained in ng/g, 40.3 morphine, 3.6 codeine, 442 BE, 186 methadone and 45.9 EDDP.


Subject(s)
Chromatography, Liquid/methods , Cocaine/analysis , Mass Spectrometry/methods , Methadone/analysis , Opiate Alkaloids/analysis , Umbilical Cord/chemistry , Drug Stability , Female , Humans , Least-Squares Analysis , Pregnancy , Reproducibility of Results , Sensitivity and Specificity
18.
J Anal Toxicol ; 33(5): 243-52, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19671243

ABSTRACT

A validated method for quantifying methadone, 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine, cocaine, benzoylecgonine, 6-acetylmorphine, morphine, and codeine in human placenta by liquid chromatography-ion trap mass spectrometry is described. Specimens (1 g) were homogenized and subjected to solid-phase extraction. Chromatographic separation was performed on a Synergi Polar RP column with a gradient of 0.1% formic acid and acetonitrile. The method was linear from 10 to 2000 ng/g for methadone and 2.5 to 500 ng/g for other analytes. Limits of detection were 0.25-2.5 ng/g, imprecisions < 9.1%CV, analytical recoveries 84.4-113.3%, extraction efficiencies > 46%, matrix effects -8.0-129.9%, and process efficiencies 24.2-201.0%. Method applicability was demonstrated by analysis of five placenta specimens from opioid-dependent women receiving methadone pharmacotherapy, with methadone doses ranging from 65 to 95 mg on the day of delivery. These are the first data on placenta concentrations of methadone and metabolites after controlled drug administration. Detection of other common drugs of abuse in placenta will also improve our knowledge of the usefulness of this matrix for detecting in utero drug exposure and studying disposition of drugs in the maternal-fetal dyad.


Subject(s)
Analgesics, Opioid/analysis , Cocaine/analysis , Methadone/analysis , Morphine/analysis , Placenta/chemistry , Substance Abuse Detection/methods , Adult , Analgesics, Opioid/metabolism , Chromatography, High Pressure Liquid , Cocaine/analogs & derivatives , Cocaine/metabolism , Female , Humans , Methadone/metabolism , Morphine/metabolism , Morphine Derivatives/analysis , Morphine Derivatives/metabolism , Placenta/metabolism , Pregnancy , Reproducibility of Results , Spectrometry, Mass, Electrospray Ionization , Young Adult
19.
Forensic Sci Int ; 188(1-3): 144-51, 2009 Jul 01.
Article in English | MEDLINE | ID: mdl-19406593

ABSTRACT

A LCMS method was developed and validated for the simultaneous determination of buprenorphine (BUP), norbuprenorphine (NBUP), buprenorphine-glucuronide (BUP-Gluc) and norbuprenorphine-glucuronide (NBUP-Gluc) in human umbilical cord. Quantification was achieved by selected ion monitoring of precursor ions m/z 468.4 for BUP; 414.3 for NBUP; 644.4 for BUP-Gluc and 590 for NBUP-Gluc. BUP and NBUP were identified by MS(2), with m/z 396, 414 and 426 for BUP, and m/z 340, 364 and 382 for NBUP. Glucuronide conjugates were identified by MS(3) with m/z 396 and 414 for BUP-Gluc and m/z 340 and 382 for NBUP-Gluc. The assay was linear 1-50 ng/g. Intra-day, inter-day and total assay imprecision (%RSD) were <14.5%, and analytical recovery ranged from 94.1% to 112.3% for all analytes. Extraction efficiencies were >66.3%, and process efficiency >73.4%. Matrix effect ranged, in absolute value, from 3.7% to 7.4% (CV<21.8%, n=8). The method was selective with no endogenous or exogenous interferences from 41 compounds evaluated. Sensitivity was high with limits of detection of 0.8 ng/g. In order to prove method applicability, an authentic umbilical cord obtained from an opioid-dependent pregnant woman receiving BUP pharmacotherapy was analyzed. Interestingly, BUP was not detected but concentrations of the other metabolites were NBUP-Gluc 13.4 ng/g, BUP-Gluc 3.5 ng/g and NBUP 1.2 ng/g.


Subject(s)
Buprenorphine/analogs & derivatives , Buprenorphine/analysis , Glucuronides/analysis , Narcotic Antagonists/analysis , Umbilical Cord/chemistry , Buprenorphine/therapeutic use , Chromatography, Liquid , Female , Forensic Toxicology , Humans , Narcotic Antagonists/therapeutic use , Opioid-Related Disorders/rehabilitation , Pregnancy , Tandem Mass Spectrometry
20.
Anal Bioanal Chem ; 393(8): 1977-90, 2009 Apr.
Article in English | MEDLINE | ID: mdl-19241063

ABSTRACT

A method for the simultaneous quantification of 20 cocaine, amphetamine, opiate, and nicotine analytes in meconium, the first neonatal feces, by liquid chromatography tandem mass spectrometry was developed and validated. Specimen preparation included methanol homogenization and solid phase extraction. Two injections were required to achieve sufficient sensitivity and linear dynamic range. Linearity ranged from 0.5-25 up to 500 ng/g (250 ng/g p-hydroxymethamphetamine), and correlation coefficients were >0.996. Imprecision was <10.0% CV, analytical recovery 85.5-123.1%, and extraction efficiencies >46.7% at three concentrations across the linear range. Despite significant matrix effects of -305.7-40.7%, effects were similar for native and deuterated analytes. No carryover, endogenous or exogenous interferences were observed, with analyte stability at room temperature, 4 degrees C, and -20 degrees C and on the autosampler >70%, except for 6-acetylmorphine, hydrocodone, oxycodone, and morphine. Method applicability was demonstrated by analyzing meconium from drug-exposed neonates.


Subject(s)
Amphetamine/analysis , Cocaine/analysis , Meconium/chemistry , Meconium/metabolism , Narcotics/analysis , Substance Abuse Detection/methods , Chromatography, Liquid , Feces/chemistry , Humans , Infant, Newborn , Sensitivity and Specificity , Substance-Related Disorders , Tandem Mass Spectrometry
SELECTION OF CITATIONS
SEARCH DETAIL
...